Latest News - Glaucoma

Friday, November 17, 2017 | Clinical Trials, Glaucoma, Implandata Ophthalmic Products, IOP

Successful First-in-Human Testing of Implandata’s Next-Generation Eyemate Micro-Sensor for Improved Monitoring of Glaucoma Patients

Implandata Ophthalmic Products reported that its next-generation Eyemate micro-sensor implant for intraocular placement has successfully passed first-in-human validation.  “Thi…

Read the full story

Saturday, November 11, 2017 | Clinical Trials, Glaucoma, Ivantis

Ivantis FDA Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery Meets Endpoints, Exceeds Outcomes of Past MIGS Trials

Ivantis announced that the HORIZON pivotal study has met both the 2-year primary and secondary pre-established endpoints. Outcomes exceed those of any MIGS pivotal trial to date. Ivantis previously an…

Read the full story

Saturday, November 11, 2017 | Clinical Trials, Glaucoma

Ivantis FDA Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS) Meets Endpoints, Exceeds Outcomes of Past MIGS Trials

Ivantis, developer of the Hydrus Microstent, announced that the HORIZON pivotal study has met both the 2-year primary and secondary pre-established endpoints. Outcomes exceed those of any MIGS pivotal…

Read the full story

Friday, November 10, 2017 | Glaucoma, Medical Studies, New World Medical

Nathan Radcliffe, MD, to Present Latest Data on Kahook Dual Blade (KDB) at AAO 2017

New World Medical announced that data will be presented at the American Academy of Ophthalmology 121st Annual Meeting (AAO 2017) in New Orleans. Nathan Radcliffe, MD, cataract and glaucoma surgeon at …

Read the full story

Friday, November 03, 2017 | Earnings & Financials, Glaucoma, Nicox

Nicox Highlights Vyzulta Approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives

Nicox highlighted recent regulatory progress, with the approval in the United States of its partnered product, Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), and provided an overview of th…

Read the full story

Friday, November 03, 2017 | Glaucoma, Medical Studies

Report: Combination Therapies to Boost the Glaucoma Therapeutics Market

Technavio market research analysts forecast the global glaucoma therapeutics market to grow at a CAGR of close to 4% during the forecast period, according to their latest report. The market study cove…

Read the full story

Wednesday, November 01, 2017 | Glaucoma, Ivantis

Ivantis Completes Premarket Approval Submission for the Hydrus Microstent for Minimally Invasive Glaucoma Surgery

Ivantis, developer of thel Hydrus Microstent, announced that it has submitted its final premarket approval (PMA) module to the FDA for market approval. The HORIZON pivotal trial is a 556-patient, pros…

Read the full story

Tuesday, October 31, 2017 | Glaucoma, Mobius Therapeutics

Mitosol's Orphan Drug Designation is Expanded for All Glaucoma Surgery

Mobius Therapeutics has expanded its orphan drug designation from the FDA for its platform product, Mitosol, to now read "Treatment of refractory glaucoma as an adjunct to surgery." By expan…

Read the full story

Friday, October 20, 2017 | Glaucoma, Partnerships, Nicox

Nicox Enters Research Collaboration with Re-Vana Therapeutics to Explore Drug Delivery Platform for the Reduction of IOP

Nicox SA and Re-Vana Therapeutics announced that they have entered into a research collaboration to explore combining Nicox’s next generation of stand-alone nitric oxide (NO)-donors with Re-Vana…

Read the full story

Tuesday, October 17, 2017 | Glaucoma

iSTAR Medical Completes Enrollment of First-in-Human MIGS Trial

iSTAR Medical announced the completion of enrollment in their first-in-human microinvasive glaucoma surgery (MIGS) trial for the MINIject device. The first-in-human trial is a prospective, ope…

Read the full story

Friday, October 13, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa

In their review of Aerie Pharmaceuticals' product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, the members of Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA provide…

Read the full story

Friday, October 13, 2017 | Glaucoma, Medical Studies, New World Medical

Dr. Kaweh Mansouri Presented Kahook Dual Blade Clinical Data at 2017 ESCRS Congress

New World Medical announced data was presented comparing the IOP lowering efficacy of cataract extraction (CE) combined with either goniotomy performed with the Kahook Dual Blade (KDB, New World Medic…

Read the full story

Wednesday, October 11, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Climbs After FDA Briefing Concurs With Efficacy Claims

Aerie Pharmaceuticals has received good news going into its FDA advisory committee meeting. The FDA agreed with the efficacy conclusion Aerie reached to support its bid for approval of glaucoma and oc…

Read the full story

Tuesday, October 10, 2017 | Glaucoma, Partnerships, Nicox , Psivida

Nicox and pSivida Enter Strategic Collaboration Agreement to Develop Sustained-Release Drug to Lower Intraocular Pressure in Patients with Glaucoma

Nicox and pSivida announced their entry into a collaboration agreement to explore the potential of combining Nicox's nitric oxide (NO)-donating compounds with pSivida's bioerodible sustained-r…

Read the full story

Thursday, October 05, 2017 | Glaucoma, Patents

New US Patent Allowance Granted to AXIM Biotechnologies for Cannabinoid Ophthalmic Solutions for Glaucoma and Conjunctivitis

AXIM Biotechnologies was granted a patent that claims the use of an ophthalmic solution comprising cannabinoids for the treatment of glaucoma and symptomatic relief of conjunctival inflammation. The U…

Read the full story
Load More